X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES UNICHEM LAB VENUS REMEDIES/
UNICHEM LAB
 
P/E (TTM) x -836.6 32.8 - View Chart
P/BV x 0.2 3.5 7.1% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 VENUS REMEDIES   UNICHEM LAB
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
UNICHEM LAB
Mar-16
VENUS REMEDIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs218334 65.3%   
Low Rs82174 47.2%   
Sales per share (Unadj.) Rs365.6146.9 248.9%  
Earnings per share (Unadj.) Rs1.511.9 12.5%  
Cash flow per share (Unadj.) Rs37.916.2 234.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs382.5105.1 363.9%  
Shares outstanding (eoy) m11.4490.84 12.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.41.7 23.7%   
Avg P/E ratio x101.021.4 472.8%  
P/CF ratio (eoy) x4.015.7 25.2%  
Price / Book Value ratio x0.42.4 16.2%  
Dividend payout %016.8 0.0%   
Avg Mkt Cap Rs m1,71723,073 7.4%   
No. of employees `0001.05.7 18.0%   
Total wages/salary Rs m3242,558 12.7%   
Avg. sales/employee Rs Th4,100.72,352.5 174.3%   
Avg. wages/employee Rs Th318.0450.9 70.5%   
Avg. net profit/employee Rs Th16.7190.4 8.8%   
INCOME DATA
Net Sales Rs m4,18313,346 31.3%  
Other income Rs m20192 10.5%   
Total revenues Rs m4,20313,538 31.0%   
Gross profit Rs m8121,639 49.5%  
Depreciation Rs m417390 106.9%   
Interest Rs m38029 1,318.8%   
Profit before tax Rs m351,412 2.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-4 0.0%   
Extraordinary Inc (Exp) Rs m0-35 0.0%   
Tax Rs m18293 6.2%   
Profit after tax Rs m171,080 1.6%  
Gross profit margin %19.412.3 158.0%  
Effective tax rate %51.620.7 248.8%   
Net profit margin %0.48.1 5.0%  
BALANCE SHEET DATA
Current assets Rs m2,7715,979 46.3%   
Current liabilities Rs m1,9312,432 79.4%   
Net working cap to sales %20.126.6 75.5%  
Current ratio x1.42.5 58.3%  
Inventory Days Days12563 198.3%  
Debtors Days Days5460 89.0%  
Net fixed assets Rs m5,3286,403 83.2%   
Share capital Rs m114182 63.0%   
"Free" reserves Rs m4,1779,293 45.0%   
Net worth Rs m4,3769,548 45.8%   
Long term debt Rs m1,911230 829.2%   
Total assets Rs m8,42812,843 65.6%  
Interest coverage x1.150.0 2.2%   
Debt to equity ratio x0.40 1,809.2%  
Sales to assets ratio x0.51.0 47.8%   
Return on assets %4.78.6 54.5%  
Return on equity %0.411.3 3.4%  
Return on capital %6.614.3 46.0%  
Exports to sales %029.2 0.0%   
Imports to sales %20.56.3 323.4%   
Exports (fob) Rs mNA3,900 0.0%   
Imports (cif) Rs m858847 101.4%   
Fx inflow Rs m04,356 0.0%   
Fx outflow Rs m8581,162 73.8%   
Net fx Rs m-8583,194 -26.9%   
CASH FLOW
From Operations Rs m4691,119 41.9%  
From Investments Rs m29-853 -3.4%  
From Financial Activity Rs m-464-334 138.7%  
Net Cashflow Rs m35-68 -50.5%  

Share Holding

Indian Promoters % 32.9 50.1 65.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 15.1 1.2%  
FIIs % 0.6 3.0 19.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 31.7 209.5%  
Shareholders   20,121 20,176 99.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   TTK HEALTHCARE  SUVEN LIFE  STERLING BIOTECH  ELDER PHARMA  AUROBINDO PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - GSK PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS